Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III - PubMed (original) (raw)
Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III
H Mitsuya et al. Science. 1984.
Abstract
A recently discovered member of the human T-cell leukemia virus (HTLV) family of retroviruses has been etiologically linked to the acquired immune deficiency syndrome (AIDS). This virus, which has been designated HTLV-III, is tropic for OKT4-bearing (helper-inducer) T cells. Moreover, the virus is cytopathic for these cells. Suramin is a drug used in the therapy of Rhodesian trypanosomiasis and onchocerciasis, and it is known to inhibit the reverse transcriptase of a number of retroviruses. Suramin has now been found to block in vitro the infectivity and cytopathic effect of HTLV-III at doses that are clinically attainable in human beings.
Similar articles
- Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitro.
Mitsuya H, Matsushita S, Yarchoan R, Broder S. Mitsuya H, et al. Princess Takamatsu Symp. 1984;15:277-88. Princess Takamatsu Symp. 1984. PMID: 6085846 Review. - Pharmacological inhibition of infectivity of HTLV-III in vitro.
Mitsuya H, Matsushita S, Harper ME, Broder S. Mitsuya H, et al. Cancer Res. 1985 Sep;45(9 Suppl):4583s-4587s. Cancer Res. 1985. PMID: 2990689 - Implications of the discovery of HTLV-III for the treatment of AIDS.
Yarchoan R, Mitsuya H, Matsushita S, Broder S. Yarchoan R, et al. Cancer Res. 1985 Sep;45(9 Suppl):4685s-4688s. Cancer Res. 1985. PMID: 2410113 Clinical Trial. - Suramin in the treatment of AIDS: mechanism of action.
De Clercq E. De Clercq E. Antiviral Res. 1987 Jan;7(1):1-10. doi: 10.1016/0166-3542(87)90034-9. Antiviral Res. 1987. PMID: 2432836 Review.
Cited by
- Selected Milestones in Antiviral Drug Development.
De Clercq E. De Clercq E. Viruses. 2024 Jan 23;16(2):169. doi: 10.3390/v16020169. Viruses. 2024. PMID: 38399945 Free PMC article. Review. - The bumpy road of purinergic inhibitors to clinical application in immune-mediated diseases.
Wyss MT, Heuer C, Herwerth M. Wyss MT, et al. Neural Regen Res. 2024 Jun 1;19(6):1206-1211. doi: 10.4103/1673-5374.386405. Epub 2023 Oct 2. Neural Regen Res. 2024. PMID: 37905866 Free PMC article. - Long-Term Effects of Suramin on Renal Function in Streptozotocin-Induced Diabetes in Rats.
Chyła-Danił G, Sałaga-Zaleska K, Kreft E, Stumski O, Krzesińska A, Sakowicz-Burkiewicz M, Kuchta A, Jankowski M. Chyła-Danił G, et al. Int J Mol Sci. 2023 Sep 28;24(19):14671. doi: 10.3390/ijms241914671. Int J Mol Sci. 2023. PMID: 37834118 Free PMC article. - Synthesis of Novel Suramin Analogs With Anti-Proliferative Activity via FGF1 and FGFRD2 Blockade.
Parveen N, Lin YL, Chou RH, Sun CM, Yu C. Parveen N, et al. Front Chem. 2022 Jan 3;9:764200. doi: 10.3389/fchem.2021.764200. eCollection 2021. Front Chem. 2022. PMID: 35047478 Free PMC article. - 1984-Discovery of the First Anti-HIV Drug, Suramin.
De Clercq E. De Clercq E. Viruses. 2021 Aug 19;13(8):1646. doi: 10.3390/v13081646. Viruses. 2021. PMID: 34452510 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources